These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 16390761

  • 1. Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.
    Werner HM, Franke HR, Vermes I.
    Climacteric; 2005 Sep; 8(3):294-9. PubMed ID: 16390761
    [Abstract] [Full Text] [Related]

  • 2. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells.
    Seeger H, Rakov V, Mueck AO.
    Horm Metab Res; 2005 Aug; 37(8):468-73. PubMed ID: 16138258
    [Abstract] [Full Text] [Related]

  • 3. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
    Jansen GH, Franke HR, Wolbers F, Brinkhuis M, Vermes I.
    Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
    Mueck AO, Seeger H, Wallwiener D.
    Climacteric; 2003 Sep; 6(3):221-7. PubMed ID: 14567770
    [Abstract] [Full Text] [Related]

  • 5. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells.
    Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO.
    Menopause; 2005 Sep; 12(4):468-74. PubMed ID: 16037763
    [Abstract] [Full Text] [Related]

  • 6. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
    Mirkin S, Wong BC, Archer DF.
    Fertil Steril; 2005 Aug; 84(2):485-91. PubMed ID: 16084894
    [Abstract] [Full Text] [Related]

  • 7. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Sioulas V, Rizos D, Caramalis G, Botsis D, Creatsas G.
    Maturitas; 2005 Apr 11; 50(4):321-30. PubMed ID: 15780533
    [Abstract] [Full Text] [Related]

  • 8. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM.
    Breast Cancer Res Treat; 2007 Jan 11; 101(2):125-34. PubMed ID: 16841178
    [Abstract] [Full Text] [Related]

  • 9. Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.
    Gao ZO, Gao ZP, Fields JZ, Boman BM.
    Anticancer Res; 2002 Jan 11; 22(3):1379-83. PubMed ID: 12168814
    [Abstract] [Full Text] [Related]

  • 10. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
    Power KA, Thompson LU.
    Breast Cancer Res Treat; 2003 Oct 11; 81(3):209-21. PubMed ID: 14620916
    [Abstract] [Full Text] [Related]

  • 11. Growth response of colon cancer cell lines to selective estrogen receptor modulators.
    Picariello L, Fiorelli G, Martineti V, Tognarini I, Pampaloni B, Tonelli F, Brandi ML.
    Anticancer Res; 2003 Oct 11; 23(3B):2419-24. PubMed ID: 12894523
    [Abstract] [Full Text] [Related]

  • 12. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
    Seeger H, Wallwiener D, Mueck AO.
    Horm Metab Res; 2003 Feb 11; 35(2):76-80. PubMed ID: 12734785
    [Abstract] [Full Text] [Related]

  • 13. Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
    Seeger H, Wallwiener D, Mueck AO.
    Gynecol Endocrinol; 2008 Oct 11; 24(10):576-9. PubMed ID: 19012101
    [Abstract] [Full Text] [Related]

  • 14. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors.
    Chen FP, Chien MH, Chen HY, Huang TS, Ng YT.
    Taiwan J Obstet Gynecol; 2013 Sep 11; 52(3):365-73. PubMed ID: 24075375
    [Abstract] [Full Text] [Related]

  • 15. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
    Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, Jordan VC.
    Cancer Res; 2002 Aug 01; 62(15):4419-26. PubMed ID: 12154049
    [Abstract] [Full Text] [Related]

  • 16. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells.
    Neubauer H, Yang Y, Seeger H, Fehm T, Cahill MA, Tong X, Ruan X, Mueck AO.
    Menopause; 2011 Aug 01; 18(8):845-50. PubMed ID: 21532513
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells.
    Xu B, Kitawaki J, Koshiba H, Ishihara H, Kiyomizu M, Teramoto M, Kitaoka Y, Honjo H.
    Maturitas; 2007 Feb 20; 56(2):142-52. PubMed ID: 16962266
    [Abstract] [Full Text] [Related]

  • 18. Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium.
    Mirkin S, Archer DF.
    Maturitas; 2007 Aug 20; 57(4):338-46. PubMed ID: 17478063
    [Abstract] [Full Text] [Related]

  • 19. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
    Bläuer M, Heinonen PK, Rovio P, Ylikomi T.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):13-8. PubMed ID: 18638473
    [Abstract] [Full Text] [Related]

  • 20. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T, Kolodziejczyk J, Krzysiek J, Basta A, Sztefko K, Kurek S, Stachura J, Gregoraszczuk EL.
    Gynecol Endocrinol; 2002 Aug 11; 16(4):319-29. PubMed ID: 12396561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.